RVL Pharmaceuticals plc (RVLPQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Dec 26, 2024, 4:00 PM EST

RVL Pharmaceuticals Statistics

Total Valuation

RVL Pharmaceuticals has a market cap or net worth of 111. The enterprise value is 38.99 million.

Market Cap 111
Enterprise Value 38.99M

Important Dates

The next estimated earnings date is Tuesday, March 25, 2025.

Earnings Date Mar 25, 2025
Ex-Dividend Date n/a

Share Statistics

RVL Pharmaceuticals has 111.41 million shares outstanding.

Current Share Class n/a
Shares Outstanding 111.41M
Shares Change (YoY) n/a
Shares Change (QoQ) +0.05%
Owned by Insiders (%) 2.76%
Owned by Institutions (%) n/a
Float 96.50M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
PB Ratio 0.00
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings -0.57
EV / Sales 1.06
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF -0.82

Financial Position

The company has a current ratio of 0.38, with a Debt / Equity ratio of 3.56.

Current Ratio 0.38
Quick Ratio 0.31
Debt / Equity 3.56
Debt / EBITDA n/a
Debt / FCF -1.22
Interest Coverage -33.53

Financial Efficiency

Return on equity (ROE) is -182.44% and return on invested capital (ROIC) is -28.03%.

Return on Equity (ROE) -182.44%
Return on Assets (ROA) -23.65%
Return on Capital (ROIC) -28.03%
Revenue Per Employee 295,352
Profits Per Employee -546,128
Employee Count 125
Asset Turnover 0.35
Inventory Turnover 6.93

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -95.83% in the last 52 weeks. The beta is 26.78, so RVL Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y) 26.78
52-Week Price Change -95.83%
50-Day Moving Average n/a
200-Day Moving Average n/a
Relative Strength Index (RSI) 48.01
Average Volume (20 Days) 33,920

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) 0.14

Income Statement

In the last 12 months, RVL Pharmaceuticals had revenue of 36.92 million and -68.27 million in losses. Loss per share was -0.70.

Revenue 36.92M
Gross Profit 30.39M
Operating Income -39.77M
Pretax Income -68.54M
Net Income -68.27M
EBITDA -39.39M
EBIT -39.77M
Loss Per Share -0.70
Full Income Statement

Balance Sheet

The company has 19.16 million in cash and 58.15 million in debt, giving a net cash position of -38.99 million or -0.35 per share.

Cash & Cash Equivalents 19.16M
Total Debt 58.15M
Net Cash -38.99M
Net Cash Per Share -0.35
Equity (Book Value) 16.33M
Book Value Per Share 0.16
Working Capital -42.64M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -44.41 million and capital expenditures -3.08 million, giving a free cash flow of -47.49 million.

Operating Cash Flow -44.41M
Capital Expenditures -3.08M
Free Cash Flow -47.49M
FCF Per Share -0.43
Full Cash Flow Statement

Margins

Gross margin is 82.31%, with operating and profit margins of -107.73% and -184.91%.

Gross Margin 82.31%
Operating Margin -107.73%
Pretax Margin -185.66%
Profit Margin -184.91%
EBITDA Margin -106.69%
EBIT Margin -107.73%
FCF Margin n/a

Dividends & Yields

RVL Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -25.65%
Shareholder Yield -25.65%
Earnings Yield -69,871,200.00%
FCF Yield -42,623,361.10%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

RVL Pharmaceuticals has an Altman Z-Score of -10.42. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -10.42
Piotroski F-Score n/a